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health concerns, numerous countries 
have expressed interest in conducting 
or are currently conducting clinical 
and epidemiological studies. Here we 
report on a large international and 
multidisciplinary collaborative eﬀ ort 
to generate standardised clinical and 
epidemiological research protocols 
and questionnaires for Zika virus.
The global community has 
recognised the need for standardised 
investigations and data collection 
following the outbreaks of avian 
influenza (H5N1, H7N9) and during 
the H1N1 pandemic of 2009.10 
Since 2011, two international and 
well-represented networks (the 
International Severe Acute Respiratory 
and Emerging Infection Consortium 
[ISARIC] and the Consortium for 
the Standardization of Influenza 
Seroepidemiology [CONSISE]) have 
been working in collaboration with 
WHO towards the standardisation 
Harmonisation of Zika 
virus research protocols 
to address key public 
health concerns
Prior to 2013–14, Zika virus infection 
was described as a mild febrile illness 
with clinical symptoms.1 However, the 
emergence of Zika virus in the Paciﬁ c 
and the Americas, the sharp increase 
in cases of Guillain-Barré syndrome 
(GBS), and the birth of babies 
with neurological complications 
such as microcephaly2,3 in several 
countries led to the Declaration 
of a National Emergency in Public 
Health by the Brazilian Ministry of 
Health in November, 2015,4 the 
Pan American Health Organization 
(PAHO) to issue an Epidemiological 
Alert on May 7, 2015,5 and WHO to 
declare a public health emergency of 
international concern on Feb 1, 2016.6 
The emergency status was maintained 
in a recent meeting of the Emergency 
Committee on Zika virus.7
While the evidence linking Zika 
virus infection and GBS in adults and 
separately between microcephaly and 
other neurological conditions in the 
fetuses of pregnant women is strong 
and growing,8,9 many key research 
and public health questions need to 
be addressed through comprehensive 
epidemiological studies to better 
understand the extent of Zika virus 
infection and the diseases Zika virus 
causes in humans and their oﬀ spring. 
WHO and PAHO have convened 
several meetings to discuss research 
needs and questions during which 
partners, diverse organisations, and 
institutions have identiﬁ ed research 
gaps and explicitly established 
research priorities to tackle key 
public health questions raised by this 
outbreak. To address these key public 
For ISARIC see https://isaric.
tghn.org/
For CONSISE see https://consise.
tghn.org/
Study protocol to address 
public health question
Primary objectives of standardised protocol
What are the risk factors for microcephaly (and/or 
congenital Zika virus syndrome)?
Case-control study for 
microcephaly 
Identify and quantify risk factors for microcephaly (and congenital Zika 
virus syndrome when clear deﬁ nition is available)
What are the risk factors for Guillain-Barré syndrome? Case-control study for 
Guillain-Barré syndrome
Identify and quantify risk factors for Guillain-Barré syndrome 
What is the clinical presentation spectrum of Zika virus 
infection in pregnant women?
What is the absolute risk of microcephaly and other 
birth defects by gestational age, rash, viraemia, and 
other co-factors?
Cohort study of pregnant 
women
Measure Zika virus infection in pregnant women
Describe the clinical spectrum of Zika virus Infection in pregnant women
Identify, describe, and quantify the spectrum of congenital deﬁ ciencies,
including microcephaly, in the fetuses/newborns of Zika virus-infected
women
What are the characteristics, grade of neurological 
impairment, evolution, complications, and mortality 
of newborns with microcephaly? 
What are the longer-term health consequences for 
infants with microcephaly or born from a mother with 
Zika virus?
Cohort study of newborns 
of pregnant women with 
documented Zika virus 
infection
Identify, describe, and quantify the spectrum of congenital deﬁ ciencies, 
including microcephaly, in the fetuses/newborns of Zika virus-infected 
women
Follow-up of infants with microcephaly or born to mothers infected 
with Zika virus
What is the risk of sexual transmission of Zika virus? Study of the persistence of 
Zika virus in body ﬂ uids
Measure Zika virus in diﬀ erent body ﬂ uids of conﬁ rmed Zika virus 
patients at diﬀ erent timepoints
What is the prevalence of Zika virus infection?
What is the role of natural immunity particularly in the 
regions with previous outbreaks?
Zika virus seroprevalence 
study in the general 
population 
Estimate seroprevalence of Zika virus in all age groups of the general 
population living in exposed and non-exposed areas
What is the natural history of Zika virus infection and 
the associated risk of severe complications and other 
outcomes in the context of co-circulating arboviruses?
Clinical characterisation 
protocol*
Analyse the full spectrum and frequency of disease manifestations 
associated with Zika virus across all age groups
Identify clinical and/or simple laboratory parameters, which 
diﬀ erentiate between Zika virus, chikungunya virus, and dengue virus 
Perform serial samples in a subgroup of patients infected with Zika virus 
to determine shedding proﬁ les over time and in diﬀ erent body ﬂ uids
*Not discussed at the Mexico WHO/PAHO meeting in June, 2016, but added to the package of standardised protocols being developed to support member states for Zika 
virus research. This protocol was developed by the International Severe Acute Respiratory and Emerging Infection Consortium, the International Research Consortium of 
Dengue Risk Assessment, Management, and Surveillance, WHO, and partners, and its development is based on previous experience of developing and implementing clinical 
protocols/tools for pre-approval and preparedness of pandemics.
Table: Seven study protocols, their objectives, and the public health questions each study will address
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Management and Surveillance (IDAMS) (TJ); and 
International Severe Acute Respiratory & Emerging 
Infection Consortium (ISARIC), Oxford, UK (GC)
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for prevention of Zika virus spread, 
surveillance, and case deﬁ nitions for 
microcephaly (and other congenital 
abnormalities related to Zika virus 
infection), to help understand the 
spread, severity, spectrum, and 
impact on the community of Zika 
virus and to guide public health 
measures, particularly for pregnant 
women and couples planning a 
pregnancy.
The geographic scope of the current 
Zika virus outbreak is vast, extending 
throughout the Americas and the 
Caribbean and into parts of Africa 
and Asia. Use of standardised research 
protocols offers the possibility of 
individual participant data analysis 
of Zika virus cohort studies and 
will ensure results of the studies 
can be compared across regions 
and countries and can potentially 
improve the quality of observational 
studies, by identifying and minimising 
biases, and thus of public health 
recommendations.
Members of the Working Group on ZIKV 
Harmonized Research, in alphabetical order, are 
listed in the appendix. The opinions expressed 
herein do not necessarily reﬂ ect the opinions of the 
institutions with which the authors are aﬃ  liated. 
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of clinical, epidemiological, and 
laboratory methods used in outbreaks. 
The process by which these 
standardised research protocols were 
generated is described in the appendix 
(p 1). Brieﬂ y, WHO, Institut Pasteur, 
and CONSISE used existing Zika 
virus and dengue research protocols 
provided by numerous institutions 
to generate six full research protocol 
drafts that harmonise (standardise) 
the key methodological aspects of 
each study design (table). A seventh 
protocol (clinical characterisation 
protocol for Zika virus infection in the 
context of co-circulating arboviruses) 
is also in development.
The standardised research protocols 
have been shared with a number of 
international experts involved in Zika 
virus research. In June, 2016, a face-to-
face meeting in Mexico City, Mexico, 
attended by more than 60 researchers 
and public health professionals from 
14 countries across the Americas 
and Europe (see appendix pp 5–11 
for agenda of meeting and list of 
participants) discussed in detail 
the research methodologies being 
proposed in the protocols and agreed 
on points for harmonisation (appendix 
p 2). Following feedback from this 
meeting with key international 
scientists and policy makers, the 
protocols were modiﬁ ed and are now 
freely available on the WHO, PAHO, 
and other partners’ websites to anyone 
who would like to use them, under a 
Creative Commons license. 
The protocols have been designed to 
maximise the likelihood that data and 
biological samples are systematically 
collected and shared rapidly in a format 
that can be easily aggregated, tabulated, 
and analysed across many different 
settings globally. We encourage any and 
all study centres to contribute to this 
eﬀ ort regardless of resource availability 
or patient volume, but the ownership 
of the primary data remains ﬁ rmly with 
the individual countries or sites.
The data collected using these 
standardised protocols will be used to 
reﬁ ne and update recommendations 
For the existing Zika virus and 
dengue research protocols see 
http://www.paho.org/zika-
research/
For the standardised research 
protocols see http://origin.who.
int/reproductivehealth/zika/zika-
virus-research-agenda/en/
See Online for appendix
